Vaxcell-Bio Therapeutics Logo

Vaxcell-Bio Therapeutics

Biotech firm developing immunotherapies for oncology and other diseases.

323990 | KO

Overview

Corporate Details

ISIN(s):
KR7323990002
LEI:
Country:
South Korea
Address:
전라남도 화순군 화순읍 산단길 12-55, 화순군

Description

Vaxcell-Bio Therapeutics is a biotechnology company specializing in the research and development of innovative immunotherapies. The company's primary focus is on oncology, developing a pipeline of cell-based and protein-based treatments, including immune cell therapies and targeted protein-degrading therapeutics. In addition to its core focus on cancer, Vaxcell-Bio is expanding its research into other areas, such as developing drug delivery system (DDS)-based therapies for conditions like macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2026-01-08 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 24.4 KB
2026-01-08 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 24.5 KB
2026-01-08 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 24.5 KB
2026-01-08 00:00
주식등의대량보유상황보고서(일반)
Korean HTML 331.4 KB
2026-01-06 00:00
[기재정정]주식매수선택권부여에관한신고
Korean HTML 22.0 KB
2026-01-06 00:00
[기재정정]주식매수선택권부여에관한신고
Korean HTML 25.5 KB
2025-09-18 00:00
기업설명회(IR)개최
Korean HTML 6.9 KB
2025-09-17 00:00
투자판단관련주요경영사항 (박스루킨-15주 (Vaxleukin-15 inj) 품목허가 변경신청 승인)
Korean HTML 11.2 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean HTML 1.2 MB
2025-07-28 00:00
기업설명회(IR)개최
Korean HTML 7.9 KB
2025-06-24 00:00
주식등의대량보유상황보고서(약식)
Korean HTML 126.2 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean HTML 1.2 MB
2025-04-15 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 24.2 KB
2025-04-08 00:00
[기재정정]주식매수선택권부여에관한신고
Korean HTML 17.0 KB
2025-04-08 00:00
[기재정정]주식매수선택권부여에관한신고
Korean HTML 17.1 KB

Automate Your Workflow. Get a real-time feed of all Vaxcell-Bio Therapeutics filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vaxcell-Bio Therapeutics

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vaxcell-Bio Therapeutics via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AVACTA GROUP PLC Logo
Clinical-stage biotech developing targeted oncology drugs with a proprietary platform.
United Kingdom
AVCT
AVADEL PHARMACEUTICALS PLC Logo
Biopharmaceutical company developing therapies for sleep disorders, focusing on narcolepsy.
United States of America
AVDL
Avalon GloboCare Corp. Logo
Develops cell-based immunotherapies and provides precision diagnostics and lab services.
United States of America
ALBT
Avidity Biosciences, Inc. Logo
Develops a class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs).
United States of America
RNA
Axogen, Inc. Logo
Develops and commercializes surgical solutions for peripheral nerve repair.
United States of America
AXGN
Axsome Therapeutics, Inc. Logo
A biopharmaceutical company developing therapies for central nervous system disorders.
United States of America
AXSM
AYTU BIOPHARMA, INC Logo
A specialty pharma company developing novel therapeutics for complex CNS diseases.
United States of America
AYTU
Azitra, Inc. Logo
Clinical-stage biopharma company developing microbiome-based therapies for skin diseases.
United States of America
AZTR
Bachem Holding AG Logo
A CDMO developing and manufacturing peptides and oligonucleotides for pharma and biotech.
Switzerland
BANB
Barinthus Biotherapeutics plc. Logo
Clinical-stage biopharma developing immunotherapies that guide T cells to control disease.
United States of America
BRNS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.